Key oncologic pathways inhibited by Erinacine A: A perspective for its development as an anticancer molecule
Parteek Prasher1, Mousmee Sharma2, Amit Kumar Sharma1
1Department of Chemistry, University of Petroleum & Energy Studies, Energy Acres, Dehradun 248007, India.
Abstract:
In the modern era, cancer can be controlled by chemotherapy treatment, and in many situations a stable disease is obtained. The significant clinical success and subsequent commercialization of naturally derived molecules have further encouraged their exploration as adjunctive therapies in cancer management. The purpose of this comprehensive review is to update the anticancer mechanisms triggered by Erinacine A and regulation of signaling pathways potentially involved in its anticancer activity.The results of preclinical research showed that Erinacin A, a therapeutically important biological metabolite isolated from the basidiomycete fungus Hericium erinaceus offers a multitude of possible chemotherapeutic applications by regulating complex signaling pathways as validated by various pharmacological in vitro and in vivo studies. As a result of Erinacin A's action on oncological signaling pathways, it resulted in induction of apoptosis, reduction of proliferation, invasiveness, generation of oxidative stress and cell cycle arrest in cancer cells.
Insights
Erinacine A, a natural compound from Hericium erinaceus, shows promise as an anticancer agent. It triggers apoptosis, reduces cancer cell proliferation, and induces cell cycle arrest through complex signaling pathways.
Area of Science:
- Natural Product Chemistry
- Oncology
- Pharmacology
Background:
- Chemotherapy is a cornerstone of modern cancer treatment, often achieving stable disease.
- Naturally derived molecules are increasingly explored as complementary cancer therapies.
- Erinacine A, a metabolite from Hericium erinaceus, has demonstrated therapeutic potential.
Purpose of the Study:
- To review the anticancer mechanisms of Erinacine A.
- To update knowledge on signaling pathways regulated by Erinacine A in cancer.
Main Methods:
- Preclinical research including in vitro and in vivo pharmacological studies.
- Analysis of Erinacine A's effects on cancer cell signaling pathways.
Main Results:
- Erinacine A induces apoptosis in cancer cells.
- It reduces cancer cell proliferation and invasiveness.
- Erinacine A causes oxidative stress and cell cycle arrest in cancer cells.
Conclusions:
- Erinacine A exhibits significant anticancer properties by modulating key oncological signaling pathways.
- Its ability to induce apoptosis, inhibit proliferation, and cause cell cycle arrest supports its potential as a chemotherapeutic agent.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:31The Intrinsic Apoptotic Pathway